April 29th 2024
These lifestyle improvements included adherence to the Mediterranean diet, improved frequency of healthy food consumption, increased physical activity, and quitting smoking, among other factors.
Vascepa Brings 36% Drop in Surgeries to Restore Blood Flow, Results Show
July 25th 2020Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, presented the latest round of data from REDUCE-IT at the American Society of Preventive Cardiology Virtual Summit 2020 this morning
Read More
VERTIS CV: Ertugliflozin Falls Short of SGLT2s on CV Outcomes, Despite Promise in Heart Failure
June 16th 2020A finding that ertugliflozin produced a 30% drop in heart failure hospitalization risk fell outside the study’s primary and secondary end points; here, the drug performed within range of its class, the sodium glucose co-transporter 2 (SGLT2) inhibitors.
Read More
Dr Darren K. McGuire Discusses Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in T2D
June 16th 2020Many in the endocrinology community still endorse using metformin first in patients with type 2 diabetes, but that isn’t really necessary any more now that sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are available, said Darren K. McGuire, MD, MHSc, professor of medicine in the Division of Cardiology, Dallas Heart Ball Chair for Research on Heart Disease in Women, Distinguished Teaching Professor, at the University of Texas Southwestern Medical Center.
Watch
Is Prevention the Future of SGLT2s? Inzucchi Offers Data That Suggest "Yes"
June 14th 2020Yale's Silvio Inzucchi, MD, who has been involved in groundbreaking trials with SGLT2 inhibitors for the past decade, shared data that show patients who did not have type 2 diabetes (T2D) when they started the DAPA-HF trial were 32% less likely to develop the disease if they took dapagliflozin (Farxiga) instead of placebo.
Read More
Cardiovascular Benefits of Vascepa Greater for Those With Diabetes, New REDUCE-IT Data Show
June 13th 2020When it comes to diabetes, lead study author Deepak L. Bhatt, MD, MPH, said clinicians and payers should weigh the considerable costs of what happens when a patient suffers a heart attack or stroke when deciding on a treatment regimen.
Read More
In a debate at the American Diabetes Association 80th Scientific Sessions, Darren K. McGuire, MD, MHSc, professor of medicine in the Division of Cardiology, Dallas Heart Ball Chair for Research on Heart Disease in Women, Distinguished Teaching Professor, at the University of Texas Southwestern Medical Center, will discuss whether sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are ready to be used for primary cardiovascular prevention.
Watch
American Heart Association Offers Guidance on Diabetes, Coronary Artery Disease
April 16th 2020Recently, it has been shown that the mechanism by which glucose is managed can have a substantial impact on cardiovascular outcomes. For this reason, along with increasing prevalence of type 2 diabetes (T2D), effective, patient-centered management of coronary artery disease (CAD) in patients with diabetes is imperative to optimize patient outcomes, the American Heart Association said.
Read More
A Q&A on Smoking Cessation With E-Cigarettes, REDUCE-IT Trial Findings
March 30th 2020The American Journal of Managed Care® (AJMC® ) interviewed Martha Gulati, MD, cardiologist at Banner – University Medicine Heart Institute, on findings of eicosapentaenoic acid (EPA) levels in relation to cardiovascular outcomes and smoking cessation with e-cigarettes. These studies are part of the 2020 American College of Cardiology / World Congress of Cardiology Virtual Experience.
Read More
Dr Javed Butler Notes Subgroup Efficacy Differences of Vericiguat in VICTORIA Trial Findings
March 29th 2020In VICTORIA, patients within the first 3 quartiles of peptide elevation had results more impressive than the overall findings. However, patients with the highest quartile did not seem to benefit. This raises the question whether the sickest of the sick patients will benefit from vericiguat, said Javed Butler, MD, MPH, MBA, chairman for the Department of Medicine at the University of Mississippi.
Watch
Dr Richard Kovacs on How ACC Is Leading the Charge for Credible Clinical Data Amid COVID-19
March 28th 2020We need more than ever credible clinical data both on the pandemic, but also how to understand how the pandemic’s going to affect patients in the cardiovascular field, said Richard Kovacs, MD, FACC, clinical cardiologist and president of the American College of Cardiology (ACC).
Watch